New tissue clearing kits and reagents for faster, accurate 3D imaging

Cambridge, UK – 13 May 2019 – Abcam’s tissue clearing kits and reagents enable easy and rapid clearing for 3D imaging of tissues and cell culture models.

Traditionally, 3D imaging of thick tissue sections and 3D cell culture models (organoids, microtissues, spheroids) has presented many technical challenges, including laborious and time-consuming tissue processing, layer-by-layer 2D imaging of thin sections and in silico 3D reconstruction. By contrast, tissue clearing reagents can expedite detailed 3D imaging by reducing the need for these steps, while providing a truer reflection of biological structures.

Developed with Visikol’s HISTO™ technology, Abcam’s tissue clearing kits use simple protocols, standard laboratory equipment, and are compatible with immunostaining, fluorescent protein and chemical dyes. Clearing is also reversible, for conventional H&E or IHC staining following 3D imaging.

To facilitate the set-up and use of Abcam’s tissue clearing kits, a selection of recombinant antibodies for key markers (Neun, S100 and Iba1) have been validated for use with the kits. Tissue clearing reagents can be purchased as part of a kit or as individual products, for greater flexibility.

www.abcam.com/tissueclearing

- ENDS -

Notes To Editors

About Abcam plc
As a global life sciences company, Abcam identifies, develops, and distributes high-quality biological reagents and tools that are crucial to research, drug discovery and diagnostics. Working across the industry, the Company supports life scientists to achieve their mission, faster. Abcam partners with life science organisations to co-create novel binders for use in drug discovery, in vitro diagnostics and therapeutics, driven by the Company's proprietary discovery platforms and world-leading, antibody expertise. By constantly innovating its binders and assays, Abcam is helping advance the global understanding of biology and causes of disease, which enables new treatments and improved health. The Company's pioneering data-sharing approach gives scientists increased confidence in their results by providing validation, user comments and peer-reviewed citations for its 110,000 products. With eleven sites globally, many of Abcam's 1,100 strong team are located in the world's leading life science research hubs, complementing a global network of services and support.

To find out more, please visit www.abcam.com and  www.abcamplc.com.

About Visikol
Visikol is a CRO focused on advanced drug discovery that is leading the fields of bio-imaging, bioinformatics and image analysis. The company conducts end-to-end drug discovery services that include both 2D and 3D in vitro models and assays, 3D whole mount tissue imaging, digital pathology and custom drug discovery projects. Visikol offers a portfolio of drug discovery services ranging from 2D and 3D cell culture model and assay development to in vitro screening, animal tissue histology and automated image processing. The focus of these services is to transform tissues into images and ultimately into quantitative data sets that can be mined for actionable insights that help clients make more informed decisions during the drug discovery process. Additionally, Visikol manufactures and sells a suite of tissue clearing reagents and 3D immuno-labeling kits. These products allow researchers to easily and rapidly image whole tissues and 3D cell culture models in 3D instead of traditional 2D sectioning.

For more information about Visikol or its services, please visikol.com.

Issued for and on behalf of Abcam plc by Instinctif Partners. 
For more information please contact:

At Abcam:
Francesca Axe
T: +44 (0)1223 696000
E: francesca.axe@abcam.com

At Instinctif Partners:
Tim Watson / Dr Katie Duffell
T: +44 (0)20 7457 2013
E: abcam@instinctif.com